Recruiting PHASE1 INTERVENTIONAL 1-arm NCT05743621

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

A Phase I, Open-Label, Dose-Finding Study of TVB-2640 Administered in Combination With Enzalutamide (Xtandi) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Sponsor: Sagimet Biosciences Inc.

Conditions Prostatic Neoplasms, Castration-Resistant

Interventions Enzalutamide TVB-2640

Updated 7 times since 2023 Last updated: Nov 17, 2025 Started: Nov 20, 2023 Primary completion: Jan 25, 2027 Completion: Jan 25, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Prostatic Neoplasms, Castration-Resistant, this trial is actively recruiting participants. The trial is conducted by Sagimet Biosciences Inc. and has accumulated 7 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Dec 2025 — Present [monthly]

Recruiting PHASE1
Jan 2025 — Dec 2025 [monthly]

Recruiting PHASE1
Sep 2024 — Jan 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Feb 2024 — Jul 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 2 earlier versions

Apr 2023 — Feb 2024 [monthly]

Not Yet Recruiting PHASE1
Mar 2023 — Apr 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sagimet Biosciences Inc.
Weill Medical College of Cornell University

Data source: Weill Medical College of Cornell University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States